I-Irbesartan CAS 138402-11-6 Purity >99.0% (HPLC) API Factory Antihypertensive
Ukunikezwa Komkhiqizi, Ukuhlanzeka Okuphezulu, Ukukhiqizwa Kwezohwebo
| Igama Lekhemikhali | I-Irbesartan |
| Omqondofana | I-BMS-186295;SR-47436;I-Aprovel;I-Avapro;2-Butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en- 4-okukodwa;2-Butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one |
| Inombolo ye-CAS | 138402-11-6 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani |
| I-Molecular Formula | I-C25H28N6O |
| Isisindo samangqamuzana | 428.54 |
| Ukuminyana | 1.30±0.10 g/cm3 |
| Ukuncibilika Emanzini | Ayincibiliki Emanzini |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Isici | I-Crystalline Powder emhlophe ukuya kokumhlophe, Incibilika kancane otshwaleni nakwi-methylene chloride, cishe ayincibiliki emanzini. |
| I-Identification Infrared Absorption | I-spectrum ye-IR ihambisana ne-spectrum etholwe nge-Irbesartan RS |
| Ukuhlonza 2 | Isikhathi sokugcina sesiqongo esikhulu ku-chromatogram yokuhlolwa sihambisana ne-Irbesartan RS |
| Ukuhlanzeka / Indlela Yokuhlaziya | >99.5% (HPLC) |
| Amanzi | <0.50% |
| Izinsimbi Ezisindayo | <0.002% |
| Izinsalela ekushiseni | <0.10% |
| Izinto Ezihlobene | (Nge-HPLC) |
| USP Ukungcola A | <0.20% |
| Noma yikuphi Ukungcola Okungaziwa | <0.10% |
| Ukungcola Okuphelele | <0.50% |
| I-Organic VolatileUkungcola | Ihlangabezana nezimfuneko ze-USP |
| I-Residual Azide | <10ppm |
| Izincibilikisi Ezisele | (Ngu-GC) |
| I-Ethanol | <5000ppm |
| I-Toluene | <890ppm |
| I-Dichloromethane | <3000ppm |
| I-N, N-Dimethylformamide | <880ppm |
| T-Butyl Methyl Ether | <5000ppm |
| Isivivinyo | 98.0~102.0% (kubalwe ngesisekelo se-anhydrous) |
| Izinga Lokuhlola | Izinga lebhizinisi;I-USP Standard |
| Ukusetshenziswa | I-API;I-Antihypertensive;Ukuze ekwelapheni hypertension |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-Irbesartan (i-CAS: C) iyisamukeli se-angiotensin II esisetshenziswa kakhulu ekwelapheni umfutho wegazi ophakeme.I-Irbesartan yasungulwa ngabakwaSanofi Research (manje abayingxenye yeSanofi-Aventis).Imakethwa ngokuhlanganyela yi-Sanofi-Aventis kanye ne-Bristol-Myers Squibb ngaphansi kwamagama okuhweba i-Aprovel, Karvea, ne-Avapro.I-Irbesartan isetshenziselwa ukwelapha umfutho wegazi ophakeme.I-Avapro yethulwa eJalimane, e-UK nase-US nge-hypertension.Njengabo bonke abamelene ne-angiotensin II receptor antagonists, i-irbesartan ikhonjiswa ekwelapheni umfutho wegazi ophakeme.I-Irbesartan ingase ibambezele ukuqhubeka kwe-nephropathy yesifo sikashukela futhi ikhonjiswe ekwehliseni ukuqhubekela phambili kwesifo sezinso ezigulini ezinesifo sikashukela sohlobo 2, umfutho wegazi ophakeme kanye ne-microalbuminuria (ngaphezu kwamahora angama-30 mg/24) noma i-proteinuria.I-Irbesartan inganciphisa nokulungiswa kabusha kukagesi kwe-myocardium, ngaleyo ndlela yehlise izinga lokufa kweziguli ezinomfutho wegazi ophakeme, iwumuthi osebenza kahle kakhulu ekwelapheni umfutho wegazi ophakeme kanye nesifo senhliziyo.
